1-(戊烷-3-基)肼盐酸盐 、 丙二腈 、 三乙胺 在
水 、 乙酸乙酯 、 Brine 作用下,
以
甲醇 为溶剂,
反应 20.0h,
以to afford 16.8 g of brown oil的产率得到5-Amino-4-cyano-[1-(1-ethylpropyl)]-3-methylpyrazole
参考文献:
名称:
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone(CRH) antagonists, useful for treating CNS and stress-related disorders
摘要:
Corticotropin releasing factor (CRF) Formula (I)的拮抗剂及其在治疗精神障碍和神经系统疾病、焦虑相关疾病、创伤后应激障碍、上行性麻痹、进食障碍以及治疗哺乳动物免疫、心血管或心脏相关疾病和与心理病理障碍和压力相关的结肠过敏性疾病中的应用。
Heterocyclyl-substituted ring-fused pyridines and pyrimidines as corticotropin releasing hormone (CRH) antagonists, useful for treating cns and stress-related disorders
申请人:——
公开号:US20010025042A1
公开(公告)日:2001-09-27
Corticotropin releasing factor (CRF) antagonists of Formula (I):
1
and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS
申请人:Bristol-Myers Squibb Pharma Company
公开号:EP1012151B1
公开(公告)日:2002-08-07
US6245769B1
申请人:——
公开号:US6245769B1
公开(公告)日:2001-06-12
US6525056B2
申请人:——
公开号:US6525056B2
公开(公告)日:2003-02-25
[EN] HETEROCYCLYL-SUBSTITUTED RING-FUSED PYRIDINES AND PYRIMIDINES AS CORTICOTROPIN RELEASING HORMONE (CRH) ANTAGONISTS, USEFUL FOR TREATING CNS AND STRESS-RELATED DISORDERS<br/>[FR] PYRIDINES A CYCLE FUSIONNE ET A SUBSTITUTION HETEROCYCLYLE, ANTAGONISTES DU FACTEUR DE LIBERATION DE LA CORTITROPINE (CRF), UTILES DANS LE TRAITEMENT DES TROUBLES LIES AU SNC ET AU STRESS
申请人:DU PONT PHARMACEUTICALS COMPANY
公开号:WO1999011643A1
公开(公告)日:1999-03-11
(EN) Corticotropin releasing factor (CRF) antagonists of formula (I) and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.(FR) L'invention porte sur des antagonistes du facteur de libération de la cortitropine (CRF), de formule (I) et leur emploi dans le traitement chez les mammifères: de troubles psychiatriques, de maladies neurologiques, de troubles liés à l'anxiété, de troubles dus au stress post-traumatique, de la paralysie supranucléaire, des troubles de la nutrition, des maladies immunologiques, cardio-vasculaires, ou cardiaques, et de l'hypersensibilité du colon liée à des dérangements psychopathologiques et au stress.